Physician profile
Mark Abumoussa
NPI 1740719889
$30,211.47
in general payments reported to CMS, 2019-2025
32 companies · $14K in 2025
The $14K reported for 2025 was more than what 96% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $684 · 2022: $1,546 · 2023: $3,144 · 2024: $11K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $28K · Honoraria: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $27,531.95 |
| Honoraria | $450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik Nro, INC. | $23,332.94 | 2023-2025 | Prospera, Biotronik |
| Abbott Laboratories | $2,349.73 | 2021-2024 | Proclaim, Eterna |
| Scilex Pharmaceuticals INC. | $988.02 | 2022-2025 | Ztlido |
| Medtronic, INC. | $550.43 | 2021-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim, Synchromedii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $480.36 | 2023-2025 | Relistor |
| Protega Pharmaceutials INC | $450.00 | 2024 | |
| Spr Therapeutics, INC | $286.84 | 2022-2025 | Sprint Pns System |
| Boston Scientific Corporation | $272.63 | 2022-2025 | Intracept, Superion Indirect Decompression System |
| Vertex Pharmaceuticals Incorporated | $167.20 | 2025 | |
| Nevro Corp. | $132.75 | 2022 | |
| Averitas Pharma INC. | $121.72 | 2023 | Qutenza |
| Spinal Simplicity, LLC | $115.20 | 2023 | Ha Minuteman G3-R |
| Pfizer INC. | $100.28 | 2023-2024 | |
| Curonix LLC | $83.71 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Relievant Medsystems, INC. | $78.58 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $76.61 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $58.77 | 2023-2024 | Xeomin |
| Electronic Waveform Lab, INC. | $57.64 | 2024 | |
| Grt US Holding, INC. | $57.35 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.30 | 2022 | |
| Almatica Pharma LLC | $53.36 | 2022-2023 | Gralise |
| Valinor Pharma, LLC | $52.12 | 2023-2024 | Movantik |
| Forte Bio-Pharma LLC | $50.42 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Depuy Synthes Sales INC. | $50.29 | 2024-2025 | Monovisc, Orthovisc |
| Azurity Pharmaceuticals, INC. | $46.25 | 2024 | Horizant |
| Avanos Medical | $35.40 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $23.14 | 2023 | Seglentis |
| Vertos Medical, INC. | $20.00 | 2024 | Mild Device Kit |
| Teva Pharmaceuticals USA, INC. | $19.21 | 2023 | Austedo |
| Foundation Fusion Solutions, LLC | $15.63 | 2021 | |
| Hikma Pharmaceuticals USA | $14.30 | 2022 | |
| Ibsa Pharma INC. | $14.29 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Abumoussa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.